Literature DB >> 8851607

Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies.

R Nau1, H W Prange, M Kinzig, A Frank, A Dressel, P Scholz, H Kolenda, F Sörgel.   

Abstract

Ceftazidime has proven to be effective for the treatment of bacterial meningitis caused by multiresistant gram-negative bacteria. Since nosocomial central nervous system infections are often accompanied by only a minor dysfunction of the blood-cerebrospinal fluid (CSF) barrier, patients with noninflammatory occlusive hydrocephalus who had undergone external ventriculostomy were studied (n = 8). Serum and CSF were drawn repeatedly after the administration of the first dose of ceftazidime (3 g over 30 min intravenously), and concentrations were determined by high-performance liquid chromatography by using UV detection. The concentrations of ceftazidime in CSF were maximal at 1 to 13 h (median, 5.5 h) after the end of the infusion and ranged from 0.73 to 2.80 mg/liter (median, 1.56 mg/liter). The elimination half-lives were 3.13 to 18.1 h (median, 10.7 h) in CSF compared with 2.02 to 5.24 h (median, 3.74 h) in serum. The ratios of the areas under the concentration-time curves in CSF and serum (AUCCSF/AUCS) ranged from 0.027 to 0.123 (median, 0.054). After the administration of a single dose of 3 g, the maximum concentrations of ceftazidime in CSF were approximately four times higher than those after the administration of 2-g intravenous doses of cefotaxime (median, 0.44 mg/liter) and ceftriaxone (median, 0.43 mg/liter) (R. Nau, H. W. Prange, P. Muth, G. Mahr, S. Menck, H. Kolenda, and F. Sörgel, Antimicrob. Agents Chemother. 37:1518-1524, 1993). The median AUCCSF/AUCS ratio of ceftazidime was slightly below that of cefotaxime (0.12), but it was 1 order of magnitude above the median AUCCSF/AUCS of ceftriaxone (0.007) (Nau et al., Antimicrob. Agents Chemother. 37:1518-1524, 1993). The concentrations of ceftazidime observed in CSF were above the MICs for most Pseudomonas aeruginosa strains. However, they are probably not high enough to be rapidly bactericidal. For this reason, the daily dose should be increased to 12 g in cases of P. aeruginosa infections of the central nervous system when the blood-CSF barrier is minimally impaired.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851607      PMCID: PMC163194     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Acute bacterial meningitis with absent or minimal cerebrospinal fluid abnormalities. A report of three cases.

Authors:  C M Moore; M Ross
Journal:  Clin Pediatr (Phila)       Date:  1973-02       Impact factor: 1.168

2.  Ceftazidime for Pseudomonas meningitis.

Authors:  K Alestig; L Olaison; M Rylander
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

3.  Evaluation of azlocillin in vitro and in discriminative animal models of infection.

Authors:  W M Scheld; J P Brodeur; J M Keeley; M R Field; W J Kelly; W J Long; O Zak
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

4.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

5.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

Authors:  R A Walstad; K B Hellum; S Blika; L G Dale; T Fredriksen; K I Myhre; G R Spencer
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

6.  Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae.

Authors:  M G Täuber; C A Doroshow; C J Hackbarth; M G Rusnak; T A Drake; M A Sande
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

7.  Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime.

Authors:  S R Norrby
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

8.  Cerebrospinal fluid lymphocytosis in acute bacterial meningitis.

Authors:  W J Powers
Journal:  Am J Med       Date:  1985-08       Impact factor: 4.965

9.  Bacterial meningitis in the absence of CSF pleocytosis.

Authors:  D B Fishbein; D L Palmer; K M Porter; W P Reed
Journal:  Arch Intern Med       Date:  1981-09

10.  Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.

Authors:  G L Drusano; H C Standiford; B Fitzpatrick; J Leslie; P Tangtatsawasdi; P Ryan; B Tatem; M R Moody; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

View more
  12 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Authors:  R Nau; M Kinzig-Schippers; F Sörgel; S Schinschke; R Rössing; C Müller; H Kolenda; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

4.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 6.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy.

Authors:  R Nau; C Lassek; M Kinzig-Schippers; A Thiel; H W Prange; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 9.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 10.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.